Dalbavancin

Products

Dalbavancin was approved in the United States and the EU in 2014 in the form of an infusion preparation (Dalvance, Xydalba). The drug has not yet been registered in many countries.

Structure and properties

Dalbavancin is a complex lipoglycopeptide semisynthetically derived from a fermentation product of -species. It exists as a mixture of structurally closely related homologous molecules. Dalbavancin is related to other glycopeptide antibiotics such as teicoplanin.

Effects

Dalbavancin (ATC J01XA04) has bactericidal properties against Gram-positive pathogens. The effects are due to inhibition of bacterial cell wall synthesis by binding to the D-Ala-D-Ala terminus in the peptidoglycan.

Indications

For the treatment of bacterial skin infections with Gram-positive pathogens (, ).

Dosage

According to the SmPC. The drug is administered as an intravenous infusion. Because of its long half-life of more than 8 days, it needs to be administered only once a week (a total of two infusions one week apart).

Contraindications

Dalbavancin is contraindicated in the presence of hypersensitivity. For complete precautions, see the drug label.

Adverse Effects

The most common possible adverse effects include nausea, diarrhea, and headache.